Runt-related transcription factor 1 promotes apoptosis and inhibits neuroblastoma progression in vitro and in vivo
Open Access
- 20 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 39 (1), 1-16
- https://doi.org/10.1186/s13046-020-01558-2
Abstract
Runt-related transcription factor 1 (RUNX1) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters and can accelerate apoptosis in various tumors. However, the regulatory mechanisms underlying RUNX1 expression in neuroblastoma (NB), a highly malignant tumor in childhood, remain largely unclear. In this study, we aimed to assess the role of RUNX1 in NB and to reveal the underlying mechanisms that may contribute to finding a potential therapeutics strategy against NB. Growth, invasion, metastasis and angiogenesis were assessed using Cell Counting Kit-8 (CCK-8) immunocytochemistry, and studies involving soft agar, cell invasion, tube formation and whole animals. The levels of expression were measured using real-time quantitative PCR for RNA, Western blot and immunostaining analyses for proteins. Luciferase reporter and chromatin immunoprecipitation assays indicated that RUNX1 directly binds within the BIRC5, CSF2RB and NFKBIA promoter regions to facilitate transcription. The level of apoptosis was assessed by determining mitochondrial membrane potential and flow cytometry. RUNX1 was highly expressed in ganglioneuroma (GN) and well-differentiated (WD) tissues relative to the poorly differentiated (PD) and undifferentiated (UD) ones. Moreover, RUNX1 effectively reduced cell viability, invasion, metastasis, angiogenesis, and promoted apoptosis in vitro and in vivo. RUNX1 reduced BIRC5 transcription and increased CSF2RB and NFKBIA transcription by directly binding BIRC5, CSF2RB and NFKBIA promoters. In addition, cytotoxic drugs, especially cisplatin, significantly increased RUNX1 expression in NB cells and promoted apoptosis. These data show that RUNX1 is an independent surrogate marker for the progression of NB and it can be used for monitoring NB prognosis during therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81372401, 81300409, 81772967)
This publication has 28 references indexed in Scilit:
- JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web frameworkNucleic Acids Research, 2017
- Augmented expression of RUNX1 deregulates the global gene expression of U87 glioblastoma multiforme cells and inhibits tumor growth in miceTumor Biology, 2017
- LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activationPLOS ONE, 2017
- The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenesBiochimica et Biophysica Acta (BBA) - General Subjects, 2016
- Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosisJournal of the Neurological Sciences, 2016
- miR-27b attenuates apoptosis induced by transmissible gastroenteritis virus (TGEV) infection via targeting runt-related transcription factor 1 (RUNX1)PeerJ, 2016
- JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profilesNucleic Acids Research, 2015
- Children's Oncology Group's 2013 blueprint for research: NeuroblastomaPediatric Blood & Cancer, 2012
- NeuroblastomaThe Lancet, 2007
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003